UP-Pharma has recently received another appreciation letter from Akesobio Pharmaceuticals for the great support from UPP team which helped to accelerate the clinical development and the regulatory approval of first in class Cadonilimab (PD-1/CTLA-4) in China. The novel bispecific Cadonilimab exhibits additional anti-tumor efficacy and clinical benefits for oncology patients. UP-Pharma looks forward to the fruitful collaboration with our sponsors to bring better medicine to patients with unmet medical needs.